AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies

• click to rate

  Posted by Two Blokes Jul 17 - Filed in Stock - 3 views
  
  AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.